GlassScriptPhysician profile
Bogdan Deaconu
NPI 1932817558
$1,233.82
in general payments reported to CMS, 2019-2025
16 companies · $903 in 2025
The $903 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.36 · 2024: $317 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $222.78 | 2025 | |
| Amgen INC. | $156.13 | 2024-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.08 | 2025 | Lifevest |
| Lilly USA, LLC | $123.96 | 2024 | Omvoh |
| Pfizer INC. | $121.66 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.96 | 2024-2025 | Jardiance, Spevigo |
| Edwards Lifesciences Corporation | $85.11 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Hemosphere |
| Merck Sharp & Dohme LLC | $50.18 | 2024-2025 | Verquvo, Keytruda |
| Esperion Therapeutics, INC. | $46.32 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $42.98 | 2024 | Hyqvia, Gammagard |
| Boston Scientific Corporation | $38.03 | 2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $31.67 | 2025 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $30.99 | 2024 | Ultomiris |
| Heartflow, INC. | $20.21 | 2025 | |
| Vivaquant INC, Dba Rhythm Express | $18.46 | 2025 | Rhythm Express |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $14.30 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bogdan Deaconu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.